As of October 2021, 3 SARS-CoV-2 vaccines are available in the United States, and all appear highly effective in the general population. Studies suggest high seroresponse to messenger RNA vaccines among maintenance dialysis patients, albeit lower than that in the general population.1-6 Data regarding adenoviral vector vaccines and predictors of vaccine nonresponse are limited by small sample sizes.7 Accordingly, we retrospectively analyzed seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients, updating an earlier report.